Well, if it's not ANP it would be one of the following.
There is nothing "complimentary" about these DMD companies - all had flat / terrible results.
Their 5 year charts tell the story.
- Capricor (muscle regeneration)
- Solid Bioscience (dystrophin restoration...GT)
- Santhera (respiratory)
- Wave Life Sciences (dystrophin restoration)
So...the timing of Sarepta CR, so close the ANP's EMA approval is intriguing.
There may be possibility that Sarepta could be partnering with a private company...
BUT - how many DMD drugs globally, are ready for 'pivotal' trial?
And how many have the "efficacy" data to "compliment" Sarepta's fledgling IP?
We'll find out by Monday / Tuesday imo.
.
Chart, page-4275
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.003(3.90%) |
Mkt cap ! $72.12M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.3¢ | 7.9¢ | $147.1K | 1.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 106165 | 2 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.003 ( 3.90 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.3¢ | 7.9¢ | 108394 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| PER (ASX) Chart |